Kiniksa Pharmaceuticals
KNSA
55 hedge funds and large institutions have $363M invested in Kiniksa Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 14 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 14
34% more funds holding
Funds holding: 41 → 55 (+14)
22% more capital invested
Capital invested by funds: $298M → $363M (+$65.2M)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
25.53% less ownership
Funds ownership: 117.03% → 91.5% (-26%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$20.3M |
| 2 |
BlackRock
New York
|
+$8.57M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.89M |
| 4 |
Millennium Management
New York
|
+$3.88M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$84.5M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$6.86M |
| 3 |
DM
Deerfield Management
New York
|
-$3.21M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.44M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1.99M |
KNSA Hedge Fund Activity: Q3 2018 in Review
55 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q3 2018, worth a combined $363M — up 22% from $298M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new KNSA positions and 14 closed out — a net gain of 14 holders — while 10 added to existing stakes and 10 trimmed.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $20.3M. The largest seller was Hillhouse Investment Management, cutting an estimated $84.5M.
- 55 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q3 2018, up from 41 in Q2 2018.
- Funds reported $363M of Kiniksa Pharmaceuticals stock for Q3 2018, up 22% quarter-over-quarter.
- 28 funds opened new Kiniksa Pharmaceuticals positions in Q3 2018 and 14 closed out, a net change of +14 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q3 2018 was ArrowMark Colorado Holdings, an estimated $20.3M added.
- The largest Kiniksa Pharmaceuticals seller in Q3 2018 was Hillhouse Investment Management, an estimated $84.5M sold.
Based on aggregated 13F filings for Q3 2018.